Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 30;18(2):68-75.
doi: 10.1900/RDS.2022.18.68.

1,5-Anhydroglucitol as a Marker of Acute Hyperglycemia in Cardiovascular Events

Marta Migała  1 , Justyna Chałubińska-Fendler  2 , Marzenna Zielińska  1
Affiliations

1,5-Anhydroglucitol as a Marker of Acute Hyperglycemia in Cardiovascular Events

Marta Migała et al. Rev Diabet Stud. .

Abstract

1,5-anhydroglucitol (1,5-AG) is a biomarker of acute hyperglycemia in diabetology and also in cardiodiabetology. It is used to monitor fluctuating glucose levels. 1,5-AG is a monosaccharide that is biochemically similar to D-glucose and originates from the nutrition. The presence of 1,5-AG in blood and tissue is nearly constant due to reabsorption in the renal proximal tubule. In acute hyperglycemia, renal reabsorption is inhibited by glucose and 1,5- AG is excreted in the urine, while its serum level decreases rapidly. 1,5-AG reflects glucose excursions over 1-3 days to 2 weeks. In this regard, low levels of serum 1,5-AG can be a clinical marker of short- term glycemic derangements such as postprandial hyperglycemia, which is an important risk factor for the pathogenesis of coronary artery disease (CAD) as low levels of 1,5-AG reflect severe plaque calcification in CAD and correlate with high-density lipoprotein cholesterol (HDL-C) levels. For these reasons, 1,5-AG may also be a marker for atherosclerosis; in fact an even better marker than HbA1c or fructosamine which are normally used. 1,5-AG may also be a predictor of cardiovascular disease, left ventricular dysfunction after acute coronary syndrome (ACS), and mortality after ACS. This articles reviews the current knowledge on 1,5-AG related to its use as predictor for cardiovascular events.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflict of interests.

Figures

Figure 1.
Figure 1.
Influence of microangiopathy and macroangiopathy on atherosclerosis [4]. Hyperglycemia is a causative factor for the development of large and small vessel disease. The two pathologies may promote atherosclerosis. In case of microangiopathy, atherosclerosis occurs in the condition of hypoxia. Additionally, microangiopathy and the process of atherosclerosis cause changes in the vasa vasorum and activate neovascularization [4].
Figure 2.
Figure 2.
Structure of 1,5 AG
See this image and copyright information in PMC

References

    1. Selvin E, Coresh J, Golden S, Brancati F, Folsom A, Steffes M. Glycemic control and coronary heart disease risk in persons with and without diabetes: The atherosclerosis risk in communities study. Arch Intern Med 2005. 165(16):1910-1916. - PubMed
    1. Deedwania P, Kosiborod M, Barrett E, Ceriello A, Isley W, Mazzone T, Raskin P. Hyperglycemia and acute coronary syndrome: A scientific statement from the american heart association diabetes committee of the council on nutrition, physical activity, and metabolism. Circulation 2008. 117(12):1610-1619. - PubMed
    1. Burchfiel C, David Curb J, Rodriguez B, Abbott R, Chiu D, Yano K. Glucose intolerance and 22-year stroke incidence: The honolulu heart program. Stroke. 25(5):951-957. - PubMed
    1. Orasanu G, Plutzky J. The Pathologic Continuum of Diabetic Vascular Disease. J Am Coll Cardiol 2009. 53(5):35-42. - PMC - PubMed
    1. Kahlon A, Pathak R. Patterns of glycemic control using glycosylated hemoglobin in diabetics. J Pharm Bioallied Sci 2011. 3(3):324-328. - PMC - PubMed

Publication types